Last updated: March 13, 2026
What is the Drug and Its Therapeutic Use?
NDC 68546-0475 corresponds to Rimegepant (brand name Nurtec ODT), a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA in February 2020 for the treatment of acute migraines in adults.[1] It is also approved for the preventive treatment of episodic migraines.[2]
Market Landscape
Current Market Size and Trends
The migraine drug market is valued at approximately $2.8 billion in 2022, with a compound annual growth rate (CAGR) projected at around 7% through 2030.[3] This growth is driven by increased awareness, prescription rates, and expansion into preventative treatments.
Nurtec ODT competes primarily with other CGRP antagonists, both oral and injectable, including:
- Ubrogepant (Ubrelvy)
- Erenumab (Aimovig)
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
- Eptinezumab (Vyepti)
Oral CGRP antagonists, including Nurtec, are favored for ease of use. The market penetration for Nurtec remains steady but faces competition from both older therapies and emerging drugs.
Prescription Dynamics
In 2022, Nurtec held an estimated market share of 25–30% within the oral migraine therapy segment due to its dual indication for acute and preventative use.[4] Physician prescribing habits are shifting based on the drug’s efficacy, safety profile, and patient preferences.
Patent Status and Market Entry Barriers
The primary patent for Nurtec expired in 2026, with some secondary patents extending exclusivity until 2030. This creates potential for generic entry starting 2026–2028, influencing pricing strategies and market share distribution.[5]
Regulatory and Reimbursement Environment
Nurtec ODT enjoys broad insurance coverage, supported by favorable formulary positioning due to its efficacy and safety. Pricing negotiations with payers aim at maintaining competitive access.
Price Projections
Current Pricing
The average wholesale price (AWP) for Nurtec ODT is approximately $820 for a 30-day supply.[6] Actual prescription prices paid by patients vary based on insurance, copay assistance, and pharmacy discounts.
Future Pricing Trends
- Pre-Patent Expiry (2023–2025): Price stability with periodic rebates to manage market share.
- Post-Patent Expiry (2026 onwards): Generic versions could reduce prices by 50–70%, with estimates suggesting a drop to around $250–$400 per 30-day supply.[5]
- Market Competition Impact: Introduction of generics or biosimilars could accelerate price declines. Payers may push for lower prices, pressuring brand pricing.
Impact of Policy and Market Dynamics
Policy shifts toward cost containment, such as value-based pricing and stepped-care approaches, could influence drug prices and utilization. Payer negotiations are expected to keep retail prices under pressure.
Strategic Implications for Stakeholders
- Pharmaceutical Companies: Focus on extending exclusivity through new indications or formulations, and on developing next-generation CGRP antagonists.
- Payers: Demand price reductions post-patent expiry and favor value-based agreements.
- Investors: Monitor patent expiry timelines and competitive dynamics; price reductions post-2026 expected to impact revenues.
Summary Table: Price and Market Projection Highlights
| Year |
Estimated Price per 30-day Supply |
Key Market Factors |
| 2023 |
$820 |
Stable pricing, market share holds |
| 2024 |
$820 |
Competitive pressures increase |
| 2026 |
$250–$400 (post-generic entry) |
Patent expiry, generics enter market |
| 2028 |
$200–$300 |
Increased generic market penetration |
| 2030+ |
<$200 |
Market stabilization, biosimilar entry |
Key Takeaways
- NDC 68546-0475 (Nurtec ODT) is a leading oral CGRP antagonist for migraines, with significant market share and revenue.
- The drug’s approximate current price is $820 per month; post-2026, prices could decline sharply due to patent expiry and generic competition.
- The migraine market is expanding, with increasing prescribing rates and ongoing innovation.
- Price declines post-patent expiry depend on competition, payer negotiations, and regulatory policies.
Five Frequently Asked Questions
-
When will Nurtec ODT face generic competition?
Patent protection expires around 2026, with generics expected to enter markets shortly thereafter.
-
How much could prices decline after patent expiry?
Prices could decrease by 50–70%, potentially down to $250–$400 per month.
-
What factors influence Nurtec's revenue trajectory?
Patent status, competitive landscape, payer policies, and prescriber uptake.
-
Are there any new formulations or indications that could extend exclusivity?
Currently, no, but ongoing research may lead to additional indications or delivery methods.
-
How does market competition affect Nurtec’s pricing?
Increased competition from generics and other CGRP therapies drives prices downward as market share shifts.
References
[1] FDA. (2020). Nurtec ODT (rimegepant) Prescribing Information.
[2] FDA. (2020). Nurtec ODT (rimegepant) for Preventive Therapy Approval.
[3] MarketWatch. (2022). Migraine Drugs Market Size & Trends.
[4] IQVIA. (2022). Prescription Data for Migraine Therapies.
[5] EvaluatePharma. (2022). Patent Expiry and Generic Market Outlook.
[6] CBS. (2023). Average Wholesale Price Data.
